Associated Papers
Recurrent resistance mutations to lirafugratinib inform treatment sequencing in FGFR2-driven tumors.
Facchinetti F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.
Tangermann C et al.
Nature Genetics, 2026
41361008 (PubMed )
Supplement: 41588_2025_2431_MOESM3_ESM.xlsx › S7_Reported_resistance
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.
Facchinetti F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.
Hsiehchen D et al.
Nature Communications, 2023
37993437 (PubMed )
Supplement: 41467_2023_43052_MOESM2_ESM.xlsx › Sup_Figure_5
Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.
Hsiehchen D et al.
Nature Communications, 2022
36463294 (PubMed )
Supplement: 41467_2022_35144_MOESM3_ESM.xlsx › Sup_Figure_5
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D et al.
Nature, 2022
35948633 (PubMed )
Supplement: 41586_2022_5066_MOESM16_ESM.xlsx › ED_Fig._2a
A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers.
Li J et al.
Frontiers in Oncology, 2021
33968743 (PubMed )
Supplement: Table_2.XLSX › table
Select a paper to view details